{"nctId":"NCT02551874","briefTitle":"A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin","startDateStruct":{"date":"2015-10-20","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus"],"count":650,"armGroups":[{"label":"Saxagliptin/Dapagliflozin/Metformin","type":"EXPERIMENTAL","interventionNames":["Drug: Saxagliptin, Onglyza","Drug: Dapagliflozin, Farxiga","Drug: Metformin"]},{"label":"Insulin Glargine, Lantos/Metformin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Glargine insulin"]}],"interventions":[{"name":"Saxagliptin, Onglyza","otherNames":["Onglyza"]},{"name":"Dapagliflozin, Farxiga","otherNames":["BMS-512148"]},{"name":"Glargine insulin","otherNames":["Lantus"]},{"name":"Metformin","otherNames":["Glucophage"]}],"eligibilityModule":{"eligibilityCriteria":"For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com\n\nInclusion Criteria:\n\n* At least 18 years of age at screening\n* HbA1c ≥ 8% and ≤ 12% at screening\n* Fasting plasma glucose (FPG) ≤ 270 mg/dL (15mmol/L)\n* Stable dose metformin ≥ 1500 mg per day with or without a stable dose of sulfonylurea (defined as at least 50% maximal dose per local label) for at least 8 weeks\n* estimated glomerular filtration rate (eGFR) \\&lt; 60 ml/ml/1.73m2\n* Body Mass Index ≤ 45.0 kg/m2\n\nExclusion Criteria:\n\n* Clinical diagnosis of Type 1 diabetes\n* History of ketoacidosis\n* Renal, hepatic or pancreatic disease\n* Impairment of renal function (defined as creatinine clearance \\[CrCl\\] \\< 60 mL/min\n* Cardiovascular or vascular diseases identified within 3 months of participationImpairment of renal function (defined as creatinine clearance \\[CrCl\\] \\< 60 mL/min","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"120 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change From Baseline in HbA1c at Week 24","description":"To examine whether the mean change from baseline in HbA1c with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin with or without SU is noninferior (noninferiority margin of 0.3%) to titrated insulin glargine plus metformin with or without SU after 24 weeks of open-label treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.67","spread":null},{"groupId":"OG001","value":"-1.54","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Total Body Weight at Week 24","description":"To compare the mean change from baseline in total body weight with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin with or without SU versus titrated insulin glargine plus metformin with or without SU after 24 weeks of open-label treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.50","spread":null},{"groupId":"OG001","value":"2.14","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Confirmed Hypoglycaemia at Week 24","description":"Hypoglycemia defined as plasma glucose ≤70 mg/dL (3.9 mmol/L)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.3","spread":null},{"groupId":"OG001","value":"38.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Achieving a Therapeutic Glycemic Response, Without Hypoglycaemia, at Week 24","description":"To compare the percentage of subjects achieving a therapeutic glycemic response, defined as HbA1c \\<7.0%, without any reported hypoglycemia, with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin with or without SU versus titrated insulin glargine plus metformin with or without SU after 24 weeks of open-label treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.9","spread":null},{"groupId":"OG001","value":"13.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Achieving a Therapeutic Glycemic Response at Week 24","description":"To examine whether the percentage of subjects achieving a therapeutic glycemic response, defined as HbA1c \\<7.0%, with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin with or without SU is noninferior (noninferiority margin of 10%) to titrated insulin glargine plus metformin with or without SU after 24 weeks of open-label treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.2","spread":null},{"groupId":"OG001","value":"33.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Mean Value of 24-hour Glucose at Week 2","description":"Change from baseline in the mean value of 24-hour glucose readings measured by Continuous Glucose Monitoring with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin with or without SU is noninferior to titrated insulin glargine plus metformin with or without SU after 2 weeks of open-label treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-48.53","spread":null},{"groupId":"OG001","value":"-28.54","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":20,"n":324},"commonTop":["Viral upper respiratory tract infection","Upper respiratory tract infection","Headache","Influenza"]}}}